ArticleNeuro-oncology advances
Neurocognitive outcome of HS-WBRT vs WBRT in patients with brain metastases: A systematic review and meta-analysis.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Whole-brain radiotherapy with simultaneous integrated boost in treatment of patients with brain metastases: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Boron neutron capture therapy prolongs survival in a rat model of multifocal brain metastases.Journal of neuro-oncology · 2026Article
- Longitudinal changes of neurocognitive function and ALPS-index in patients with brain tumors receiving brain irradiation.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Whole-brain radiation therapy (WBRT) is used prophylactically and therapeutically in patients with brain metastases, effectively controlling intracerebral tumors and reducing neurological mortality. However, WBRT poses a significant risk of cognitive decline. Hippocampus-sparing WBRT (HS-WBRT) offers a potential solution by preserving memory and other cognitive functions. This study evaluates neurocognitive outcomes of HS-WBRT compared to WBRT in patients with brain metastases. Methods: A systematic search was conducted in MEDLINE, Google Scholar, Embase, and CENTRAL for cohort studies and clinical trials reporting neurocognitive outcomes of HS-WBRT vs WBRT, up to March 2024. Non-English studies and those lacking neurocognitive outcomes were excluded. Eligible studies underwent data extraction and analysis focused on neurocognitive function testing. Results: Of 9 eligible studies, 7 were included in the quantitative analysis. HS-WBRT significantly reduced cognitive decline compared to WBRT, with improvements in Hopkins Verbal Learning Test (HVLT) scores for total recall (SMD = 0.42; Conclusion: HS-WBRT demonstrates a clear advantage over WBRT in preserving neurocognitive function in patients with brain metastases, as reflected in HVLT and MoCA scores. Future studies should further explore adverse effects and survival outcomes to guide clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.